MetaCap

Quest Diagnostics (DGX) vs Humana (HUM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Humana (HUM) has outperformed Quest Diagnostics (DGX) over the past year, gaining 71.7% versus a gain of 35.0%. Over five years, DGX leads with a +66.7% price change compared with -9.0% for HUM. Humana is the larger company by market cap ($46.84 billion vs $28.42 billion), about 1.6 times the size, while Quest Diagnostics is growing revenue faster (+11.8% vs +10.1%).

On valuation, Humana trades at a lower forward P/E (21.1x vs 21.6x for Quest Diagnostics). Quest Diagnostics offers the higher dividend yield (1.31% vs 0.91%). Quest Diagnostics converts more of its revenue into profit, with a net margin of 9.0% versus 0.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DGX+35.05%HUM+71.73%
+110%+38%-34%
Nov 21, 20251 yearNov 20, 2026
DGX+74.00%HUM-10.32%
+82%+6%-69%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DGX versus HUM key metrics
MetricDGXHUM
Share price$258.28$390.00
Market cap$28.42B$46.84B
1-day change-0.31%+2.63%
YTD return+48.84%+52.27%
1-year return+35.05%+71.73%
5-year return+66.69%-8.98%
P/E ratio (TTM)25.7338.05
Forward P/E21.5521.06
EPS (TTM)$10.04$10.25
Dividend yield1.31%0.91%
Annual dividend$3.38$3.54
Revenue (latest FY)$11.04B$129.66B
Revenue growth (YoY)+11.78%+10.11%
Net income (latest FY)$992.00M$1.19B
Gross margin33.21%—
Operating margin14.10%2.09%
Net margin8.99%0.92%
52-week high$263.19$462.87
52-week low$171.18$163.11
Distance from 52-week high-1.87%-15.74%
Analyst consensusbuybuy
Avg. price target upside-0.39%+30.98%
Average volume1.03M1.46M
Shares outstanding110.02M120.10M
Employees60,00067,060
SectorHealth CareHealth Care
IndustryMedical SpecialitiesMedical Specialities

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • HUM has outperformed DGX by 36.7 percentage points over the past year.
  • Humana trades at a higher earnings multiple (38.0x vs 25.7x trailing P/E).
  • Quest Diagnostics is more profitable, keeping 9.0 cents of every revenue dollar as net income versus 0.9 cents for Humana.

About Quest Diagnostics

DGX stock →

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Health Care · Medical Specialities · 60,000 employees

About Humana

HUM stock →

Humana Inc. provides medical and specialty insurance products in the United States.

Health Care · Medical Specialities · 67,060 employees

DGX vs HUM FAQ

Which is bigger, Quest Diagnostics or Humana?

Humana (HUM) is larger, with a market capitalization of $46.84B compared with $28.42B for Quest Diagnostics (DGX).

Which stock has performed better over the past year, DGX or HUM?

HUM returned +71.73% over the past 12 months, compared with +35.05% for DGX (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, DGX or HUM?

DGX has the lower trailing P/E at 25.7, versus 38.0 for HUM. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Quest Diagnostics or Humana?

Quest Diagnostics has the higher yield at 1.31%, compared with 0.91% for Humana.

Are Quest Diagnostics and Humana in the same industry?

Yes. Both are classified in the Medical Specialities industry within the Health Care sector.

More comparisons